Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth

por Wettersten, Hiromi I., Landesman, Yosef, Friedlander, Sharon, Shacham, Sharon, Kauffman, Michael, Weiss, Robert H.
Publicado en PLoS One (2014)

Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels

por Tan, Matthew, Wettersten, Hiromi I., Chu, Kristy, Huso, David L., Watnick, Terry, Friedlander, Sharon, Landesman, Yosef, Weiss, Robert H.
Publicado en Am J Physiol Renal Physiol (2014)

Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras

por Gidekel Friedlander, Sharon Y, Chu, Gerald C., Snyder, Eric L., Girnius, Nomeda, Dibelius, Gregory, Crowley, Denise, Vasile, Eliza, DePinho, Ronald A., Jacks, Tyler
Publicado 2009

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin

por De Cesare, Michelandrea, Cominetti, Denis, Doldi, Valentina, Lopergolo, Alessia, Deraco, Marcello, Gandellini, Paolo, Friedlander, Sharon, Landesman, Yosef, Kauffman, Michael G., Shacham, Sharon, Pennati, Marzia, Zaffaroni, Nadia
Publicado en Oncotarget (2015)

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

por Zhou, Xiaofei, Friedlander, Sharon, Kupperman, Erik, Sedarati, Farhad, Kuroda, Shingo, Hua, Zhaowei, Yuan, Ying, Yamamoto, Yuka, Faller, Douglas V., Haikawa, Kazue, Nakai, Katsuhiko, Bowen, Sharon, Dai, Yi, Venkatakrishnan, Karthik
Publicado en Clin Transl Sci (2021)

ACTR-02. DCC-2618, A NOVEL pan-KIT AND PDGFRa KINASE SWITCH CONTROL INHIBITOR, SHOWS ENCOURAGING SIGNAL IN A PATIENT (PT) WITH GLIOBLASTOMA (GBM)

por de Groot, John, George, Suzanne, Razak, Albiruni, Gordon, Michael, Janku, Filip, Ligon, Keith, Wen, Patrick, Friedlander, Sharon, Flynn, Daniel, Kaufman, Michael, Pitman, Jama, Ruiz-Soto, Rodrigo, Smith, Bryan, Westwood, Deborah, Rosen, Oliver, Reardon, David
Publicado en Neuro Oncol (2017)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

por Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., Adès, Lionel
Publicado en Leukemia (2021)

Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies

por Fischer, Melissa A., Friedlander, Sharon Y., Arrate, Maria P., Chang, Hua, Gorska, Agnieszka E., Fuller, Londa D., Ramsey, Haley E., Kashyap, Trinayan, Argueta, Christian, Debler, Sophie, Byrne, Michael, Villaume, Matthew T., Shaver, Aaron C., Senapedis, William, Landesman, Yosef, Baloglu, Erkan, Shacham, Sharon, Savona, Michael R.
Publicado en Blood Adv (2020)

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

por Gounder, Mrinal M., Zer, Alona, Tap, William D., Salah, Samer, Dickson, Mark A., Gupta, Abha A., Keohan, Mary Louise, Loong, Herbert H., D’Angelo, Sandra P., Baker, Stephanie, Condy, Mercedes, Nyquist-Schultz, Kjirsten, Tanner, Lanier, Erinjeri, Joseph P., Jasmine, Francis H., Friedlander, Sharon, Carlson, Robert, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Rashal, Tami, Ellis, Joel, Kauffman, Michael, Shacham, Sharon, Schwartz, Gary K., Abdul Razak, Albiruni Ryan
Publicado en J Clin Oncol (2016)